Trial Profile

An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T Cells in Patients With Metastatic or Recurrent Melanoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 09 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATL 001 (Primary) ; Nivolumab (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
Indications Malignant melanoma; Skin cancer
Focus Adverse reactions; First in man; Proof of concept
Acronyms THETIS
Sponsors Achilles Therapeutics

19 Sep 2024 According to Achilles Therapeutics media release, full clinical data generated from the Phase I/IIa THETIS trial in patients with recurrent or metastatic melanoma will be presented in an upcoming forum.
19 Sep 2024 According to Achilles Therapeutics media release, company today announced the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials.
19 Sep 2024 Status changed to discontinued, according to Achilles Therapeutics media release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com